Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

September 15, 2021

A Bayesian Optimal Design Advancing the Precision Medicine Approach

There is recognized heterogeneity within any given tumor‐type from patient to patient (inter‐patient heterogeneity),...

Read article

July 2, 2021

Use of Rolling-enrollment Designs to Accelerate Clinical Trials

Popular statistical designs, such as CRM (O’Quigley et al., 1990), mTPI-2 (Guo et al., 2017), and i3+3 (Liu et al.,...

Read article

June 24, 2021

Myths surrounding the use of synthetic control arms in clinical trials: Part 3

Synthetic control arms (SCAs) leverage real world data from various sources or evaluations of historical clinical data...

Read article

December 18, 2019

Year-End Roundup: Your Favorite Blog Posts of 2019

With only two weeks left for this fabulous year to end, we would like to thank all our blog subscribers and new readers...

Read article

November 5, 2019

Drug Development in Rare Diseases - Innovation in Statistical Thinking

Cytel is delighted to have Kannan Natarajan speaking at the “Complex Innovative Trial Design Symposium and East User...

Read article